FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response	: 0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* AKKARAJU SRINIVAS (Last) (First) (Middle) C/O CHINOOK THERAPEUTICS, INC. 1600 FAIRVIEW AVE. E.					2. Issuer Name and Ticker or Trading Symbol CHINOOK THERAPEUTICS, INC. [KDNY] 3. Date of Earliest Transaction (Month/Day/Year) 06/04/2021								(CI	Relationship of Reporting (Check all applicable) X Director Officer (give title below)				10% Owner Other (specify below)		
(Street) SEATTL (City)			98102 (Zip)		4. 11									inaivi	'					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					Execution Date,			Code (I		r. 5) (A) or D			4 and Securitie Benefici Owned Reporter Transaction		es Formally (D) (I) (I) (I) (I) (I) (I) (I) (I) (I) (I		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	Code (of		6. Date Exe Expiration (Month/Day	Date	Amount of		f g Security	Der Sec	. Price of lerivative lecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares	er						
Stock Option (Right to Buy)	\$16.81	06/04/2021			A		5,948		(1)	00	5/03/2031	Common Stock	5,948	\$	\$0.00	5,948		D		

Explanation of Responses:

1. The option award will fully vest upon the earlier of 1) the Issuer's next annual stockholder meeting, or 2) June 4, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Remarks:

/s/ Kirk Schumacher, Attorney- 06/08/2021 in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.